MichaelThomasSchweizerMD

Oncology • Seattle, WA

Genitourinary Oncology, Hematologic Oncology

Associate Professor of Medicine, University of Washington

Join to view full profile

Dr. Schweizer is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Schweizer's full profile

Already have an account?

Office
825 Eastlake Ave E

Seattle, WA 98109
Phone+1 206-288-1000

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2011 - 2014
University of ChicagoResidency, Internal Medicine, 2008 - 2011
Lewis Katz School of Medicine at Temple UniversityClass of 2008

Certifications & Licensure

AK State Medical License 2022 - 2026
WA State Medical License 2014 - 2025
MD State Medical License 2011 - 2015
IL State Medical License 2008 - 2011
American Board of Internal Medicine Medical Oncology

Clinical Trials

Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer Start of enrollment: 2020 Apr 27
Terminated
Phase 2
A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer Start of enrollment: 2020 Feb 06
COMPLETED
PHASE3
A Study of CART-PSMA-TGFβRDN in Patients With Metastatic Castration Resistant Prostate Cancer Start of enrollment: 2019 Nov 22
Terminated
Phase 1
Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load Start of enrollment: 2021 Apr 13
ACTIVE_NOT_RECRUITING
PHASE2
Abemaciclib (LY2835219) in Men With Heavily Treated Metastatic Castration-Resistant Prostate Cancer Start of enrollment: 2021 Jan 20
COMPLETED
PHASE2
Join now to see all

Publications & Presentations

PubMed

Docetaxel and Carboplatin for the Treatment of Patients with Metastatic Castration-resistant Prostate Cancer and Biallelic Inactivation of Genes in the Homologous Reco...
Ruben Raychaudhuri, Makayla DeJong, Matthew Rettig, Evan Y Yu, Roman Gulati
European Urology. 2025-03-01
Association of Prior PARP Inhibitor Exposure with Clinical Outcomes afterLu-PSMA-617 in Men with Castration-resistant Prostate Cancer and Mutations in DNA Homologous R...
Ruben Raychaudhuri, Abuzar Moradi Tuchayi, Soon Khai Low, Ali T Arafa, Laura S Graham
European Urology Oncology. 2025-02-06
1 citations
PET-Based TheraP Eligibility and Outcomes of VISION-Eligible Patients with Metastatic Castration-Resistant Prostate Cancer Who ReceivedLu-PSMA-617: Importance ofF-FDG-...
Ridvan Arda Demirci, Alireza Ghodsi, Roman Gulati, Sanaz Behnia, Peter S Nelson
Journal of Nuclear Medicine. 2025-01-03

Journal Articles

Association of Clonal Hematopoiesis in DNA Repair Genes with Prostate Cancer Plasma Cell-Free DNA Testing Interference
Michael T Schweizer, Petros Grivas, Heather H Cheng, Evan Y Yu, JAMA Oncology

Lectures

Genomic characterization of ductal adenocarcinoma of the prostate.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

Mevrometostat Combo Posts Strong Data in Early-Phase Prostate Cancer TrialFebruary 21st, 2025
Radiographic PFS in Metastatic CRPC More Than Doubles with Novel CombinationFebruary 13th, 2025
Fred Hutch at ASCO: Progress in Treating Metastatic Cancer, Hospice Access for Cancer Patients, Use of Machine Learning with CAR T-cell TherapyMay 23rd, 2024
Join now to see all